Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-04-19 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2023年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of Shenzhen Microchip Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, financial statements, profit distribution, board elections, and other corporate matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. It contains detailed voting statistics and legal witness statements confirming the validity of the meeting and votes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief report publication announcement or a simple regulatory filing but a comprehensive voting result announcement.
2024-04-19 Chinese
自愿披露关于西奥罗尼胶囊治疗胰腺癌临床试验申请获得受理的公告
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a clinical trial application for a new drug by the National Medical Products Administration. It contains no financial data, no financial statements, and no report content. It is an announcement about regulatory acceptance of a clinical trial application, which is a regulatory update rather than a financial or management report. The document length is short (1412 characters), and it is clearly an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-09 Chinese
关于注销回购股份及减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the cancellation of repurchased shares and the corresponding reduction of registered capital. It includes details about the share repurchase plan, the number of shares to be cancelled, the reduction in registered capital, and a notification to creditors about their rights to claim debts within a specified period. The document does not contain financial statements or detailed financial analysis but is a regulatory announcement related to capital changes and creditor notification. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2024-04-08 Chinese
关于股份回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the implementation results of a share repurchase program by Shenzhen Microchip Biotechnology Co., Ltd. It details the number of shares repurchased, the price range, the total amount spent, the approval process, and the intended use of the repurchased shares (cancellation and capital reduction). The document does not contain financial statements or detailed financial analysis but focuses on the share buyback activity and its compliance with regulations. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-04-08 Chinese
关于明确股份回购用途的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the clarification of the purpose of its share repurchase program. It details the board meetings and shareholder meetings where the share repurchase plan was approved, the financial parameters of the repurchase, and the specific intended use of the repurchased shares (all to be cancelled and reduce registered capital). The document is short (1025 characters) and focuses on the share repurchase purpose clarification rather than presenting financial statements or detailed financial data. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. It is not a full financial report, earnings release, or regulatory filing. Therefore, the correct classification is POS with high confidence.
2024-04-08 Chinese
2024年第一次债券持有人会议资料
Capital/Financing Update Classification · 95% confidence The document is titled '2024 年第一次债券持有人会议资料' which translates to '2024 First Bondholders Meeting Materials' and contains detailed information about the bondholders meeting agenda, voting procedures, legal notices, and a specific proposal regarding adjustment of convertible bond investment projects. It is not a financial report like an annual or interim report, nor is it a simple announcement. The content is focused on the bondholders meeting, including meeting rules, agenda, voting, and legal opinions, which aligns with a Capital/Financing Update related to bondholder matters. The document length is 3322 characters, which is relatively short but contains substantive meeting materials rather than just an announcement. Therefore, the best fitting category is Capital/Financing Update (CAP).
2024-04-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.